Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05379348 · ClinicalTrials.gov registry record
Davos Alzheimer's Collaborative Study: Sequential Administration of Digital Testing To Screen For Cognitive Impairment Followed By Blood Based Biomarkers To Assist With Timely Detection And Accurate Diagnosis Of Alzheimer's Disease
A clinical trial of Alzheimer Disease, sponsored by AdventHealth Translational Research Institute.
- Active
- Registry status
- 1,423
- Enrollment target
- 1
- Study location
NCT05379348 is a study of Alzheimer Disease that is active but no longer recruiting, run by AdventHealth Translational Research Institute. The registered enrollment target is 1,423 participants, below the 2,746-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (48% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05379348, a study of Alzheimer Disease, is active but no longer recruiting, sponsored by AdventHealth Translational Research Institute.
- ACTIVE NOT RECRUITING
- Registry status
- 1,423 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to investigate how we can detect Alzheimer's disease early by using an online memory test and a simple blood test. These new methods for early diagnosis could allow people to begin treatment sooner, with the potential to improve the lives of millions of people.
Conditions Studied
Interventions
- OTHER Cognitive Assessment
Study Locations (1)
Florida
- AdventHealth Translational Research Institute - Orlando
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,423 participants |
| Start Date | 2022-03-14 |
| Est. Completion | 2025-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05379348
The ClinicalTrials.gov registry entry for NCT05379348 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 1,423 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,746-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (48% lower). The listed sponsor is AdventHealth Translational Research Institute, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Alzheimer Disease appearing as the primary indexed condition, and to 1 intervention - of which Cognitive Assessment is the first listed.
NCT05379348 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT05379348 about?
NCT05379348 is a clinical study titled "Davos Alzheimer's Collaborative Study: Sequential Administration of Digital Testing To Screen For Cognitive Impairment Followed By Blood Based Biomarkers To Assist With Timely Detection And Accurate Diagnosis Of Alzheimer's Disease". The purpose of this study is to investigate how we can detect Alzheimer's disease early by using an online memory test and a simple blood test. These new methods for early diagnosis could allow people to begin treatment sooner, with the potential to improve the lives of millions of people.
What is the current status of trial NCT05379348?
This trial is currently active not recruiting. The enrollment target is 1,423 participants. The study started on 2022-03-14. Estimated completion is 2025-12.
What conditions does trial NCT05379348 study?
This clinical trial studies the following conditions: Alzheimer Disease.
What interventions are being tested in trial NCT05379348?
The interventions under investigation include: Cognitive Assessment (OTHER).
Who is sponsoring clinical trial NCT05379348?
This trial is sponsored by AdventHealth Translational Research Institute, which has 54 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05379348 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)
RECRUITING · Phase 3
-
Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease
RECRUITING · Phase 4
-
Systemic and Central Inflammation in AD
RECRUITING · Phase 2
-
I-CARE 2: Mobile Telehealth to Reduce Alzheimer'S-related Symptoms
RECRUITING · NA
-
Autologous Activated Adipose-derived Stem Cells (RB-ADSC) Injected Directly Into the Brain for Mild to Moderate Alzheimer's Disease
RECRUITING · Phase 1
-
Cognitive Neurology Unit Clinical Registry
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.